From Bench to Bedside: What Do We Know About Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-positive Breast Cancer?

Overview

Journal J Steroid Biochem Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2015 May 23

PMID 25998416

Citations 27

Authors

Victoria Shang Wu

Noriko Kanaya

Chiao Lo

Joanne Mortimer

Shiuan Chen

Affiliations

Soon will be listed here.

Abstract

Breast cancer is a heterogeneous disease. Thanks to extensive efforts from research scientists and clinicians, treatment for breast cancer has advanced into the era of targeted medicine. With the use of several well-established biomarkers, such as hormone receptors (HRs) (i.e., estrogen receptor [ER] and progesterone receptor [PgR]) and human epidermal growth factor receptor-2 (HER2), breast cancer patients can be categorized into multiple subgroups with specific targeted treatment strategies. Although therapeutic strategies for HR-positive (HR+) HER2-negative (HER2-) breast cancer and HR-negative (HR-) HER2-positive (HER2+) breast cancer are well-defined, HR+ HER2+ breast cancer is still an overlooked subgroup without tailored therapeutic options. In this review, we have summarized the molecular characteristics, etiology, preclinical tools and therapeutic options for HR+ HER2+ breast cancer. We hope to raise the attention of both the research and the medical community on HR+ HER2+ breast cancer, and to advance patient care for this subtype of disease.

Citing Articles

A diagnostic test of two-dimensional ultrasonic feature extraction based on artificial intelligence combined with blood flow Adler classification and contrast-enhanced ultrasound for predicting -positive breast cancer.

Wang K, Yang X, Yang S, Du X, Shi R, Bai W Transl Cancer Res. 2025; 14(1):640-650.

PMID: 39974394 PMC: 11833378. DOI: 10.21037/tcr-24-2182.

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma.

He C, Wang X, Chiou Y, Basappa B, Zhu T, Pandey V Cell Death Dis. 2025; 16(1):76.

PMID: 39920140 PMC: 11806102. DOI: 10.1038/s41419-025-07387-5.

Oncolytic Adenovirus for the Targeting of Paclitaxel-Resistant Breast Cancer Stem Cells.

Robert S, Roman Ortiz N, LaRocca C, Ostrander J, Davydova J Viruses. 2024; 16(4).

PMID: 38675909 PMC: 11054319. DOI: 10.3390/v16040567.

Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials.

Fazal F, Bashir M, Adil M, Tanveer U, Ahmed M, Chaudhry T Cureus. 2023; 15(5):e39780.

PMID: 37398703 PMC: 10312476. DOI: 10.7759/cureus.39780.

Cytotoxic evaluation of YSL-109 in a triple negative breast cancer cell line and toxicological evaluations.

Sixto-Lopez Y, Ordaz-Pichardo C, Gomez-Vidal J, Rosales-Hernandez M, Correa-Basurto J Naunyn Schmiedebergs Arch Pharmacol. 2023; 396(6):1211-1222.

PMID: 36694011 DOI: 10.1007/s00210-023-02396-7.

References

Gao F, Ma X, Ostmann A, Das S . GPR30 activation opposes estrogen-dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERα) phosphorylation signals. Endocrinology. 2011; 152(4):1434-47. PMC: 3060628. DOI: 10.1210/en.2010-1368. View

Witton C, Reeves J, Going J, Cooke T, Bartlett J . Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003; 200(3):290-7. DOI: 10.1002/path.1370. View

Cui X, Schiff R, Arpino G, Osborne C, Lee A . Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005; 23(30):7721-35. DOI: 10.1200/JCO.2005.09.004. View

Saini K, Loi S, de Azambuja E, Metzger-Filho O, Saini M, Ignatiadis M . Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013; 39(8):935-46. DOI: 10.1016/j.ctrv.2013.03.009. View

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua M, Pruneri G . Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2012; 24(3):661-8. DOI: 10.1093/annonc/mds430. View

Nagata Y, Lan K, Zhou X, Tan M, Esteva F, Sahin A . PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6(2):117-27. DOI: 10.1016/j.ccr.2004.06.022. View

Cato A, Nestl A, Mink S . Rapid actions of steroid receptors in cellular signaling pathways. Sci STKE. 2002; 2002(138):re9. DOI: 10.1126/stke.2002.138.re9. View

Gerdes J, Schwab U, Lemke H, STEIN H . Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983; 31(1):13-20. DOI: 10.1002/ijc.2910310104. View

Stoica A, Saceda M, Doraiswamy V, Coleman C, Martin M . Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol. 2000; 165(2):371-8. DOI: 10.1677/joe.0.1650371. View

10.

Beelen K, Opdam M, Severson T, Koornstra R, Vincent A, Wesseling J . Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Res. 2014; 16(1):R6. PMC: 3979131. DOI: 10.1186/bcr3598. View

11.

Ellis M, Coop A, Singh B, Mauriac L, Janicke F, Miller W . Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19(18):3808-16. DOI: 10.1200/JCO.2001.19.18.3808. View

12.

Samuels Y, Velculescu V . Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3(10):1221-4. DOI: 10.4161/cc.3.10.1164. View

13.

Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H . Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 1995; 270(5241):1491-4. DOI: 10.1126/science.270.5241.1491. View

14.

McKenna N, Lanz R, OMalley B . Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 1999; 20(3):321-44. DOI: 10.1210/edrv.20.3.0366. View

15.

Prat A, Baselga J . The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 2008; 5(9):531-42. DOI: 10.1038/ncponc1179. View

16.

Roskoski Jr R . The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2013; 79:34-74. DOI: 10.1016/j.phrs.2013.11.002. View

17.

Marangoni E, Poupon M . Patient-derived tumour xenografts as models for breast cancer drug development. Curr Opin Oncol. 2014; 26(6):556-61. DOI: 10.1097/CCO.0000000000000133. View

18.

LASFARGUES E, COUTINHO W, REDFIELD E . Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst. 1978; 61(4):967-78. View

19.

Tovey S, Witton C, Bartlett J, Stanton P, Reeves J, Cooke T . Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 2004; 6(3):R246-51. PMC: 400680. DOI: 10.1186/bcr783. View

20.

Wang Y, Morrison G, Gillihan R, Guo J, Ward R, Fu X . Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011; 13(6):R121. PMC: 3326563. DOI: 10.1186/bcr3067. View